Advertisement

Journal of General Internal Medicine

, Volume 30, Issue 2, pp 169–175 | Cite as

Hormone Therapy Use in Women Veterans Accessing Veterans Health Administration Care: A National Cross-Sectional Study

  • Megan R. GerberEmail author
  • Matthew W. King
  • Suzanne L. Pineles
  • Shannon Wiltsey-Stirman
  • Bevanne Bean-Mayberry
  • Sandra J. Japuntich
  • Sally G. Haskell
Original Research

ABSTRACT

The majority of women Veterans using VA (Veterans Administration) care fall in the 45–65 year-old age range. Understanding how menopause is managed in this group is of importance to optimizing their health.

OBJECTIVE

National population estimates showed a prevalence of hormone therapy (HT) use by women over 45 years of 4.7 % (2009–2010). Our study described the frequency of HT use among women Veterans in VA, and examined whether mental health (MH) was predictive of HT use.

DESIGN

This was a cross-sectional analysis of national VA administrative data for fiscal year 2009.

PARTICIPANTS

Women Veterans over the age of 45 (N = 157,195) accessing VA outpatient care were included in the analysis.

MAIN MEASURES

Logistic regression analyses using HT use as the dependent variable.

KEY RESULTS

Mean age was 59.4 years (SD =12.2, range =46–110), and 16,227 (10.3 %) of all women used HT. Hysterectomy (OR 3.99 [3.53, 4.49]) and osteoporosis (1.34 [1.27, 1.42]) were the strongest medical indicators of HT use. A total of 49,557 (31.5 %) women in the sample received at least one primary diagnosis of a MH disorder and were more likely to use HT than women with no MH diagnoses (unadjusted OR 1.56, 95 % CI [1.50, 1.61]). Women Veterans with a mood disorder (depression/bipolar) or anxiety disorder [post-traumatic stress disorder (PTSD), other anxiety diagnoses] were more likely to use HT after controlling for demographics and medical comorbidity.

CONCLUSION

The prevalence of HT use among women Veterans using VA is more than twice that of the general population. Prior work suggested that women Veterans were discontinuing HT at comparable rates, but these data demonstrate that decline in VA HT use has not kept pace with that of civilian medical care. The association of MH diagnosis with HT use suggests that MH plays an important role in VA rates. Further study is needed to understand contributing patient and provider factors.

KEY WORDS

women Veterans hormone therapy mental health 

Notes

Acknowledgements

The authors wish to acknowledge the assistance of Melissa Skanderson, MSW.

Funding to support database creation was provided by National Center for PTSD (NCPTSD), U.S. Department of Veterans Affairs, Executive Division, White River Junction, VT.

This work was supported in part by Career Development Award (Japuntich) #1IK2CX000918-01A1from the United States Department of Veterans Affairs Clinical Sciences Research and Development Service.

This study was presented in abstract form at the Society for General Internal Medicine (SGIM), 36th Annual Meeting, April 26, 2013, Denver, CO.

The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the United States Government.

Conflict of Interest

The authors declare that they do not have a conflict of interest.

REFERENCES

  1. 1.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA : the journal of the American Medical Association. Jul 17 2002;288(3):321–333.Google Scholar
  2. 2.
    Haskell SG, Bean-Mayberry B, Goulet JL, Skanderson M, Good CB, Justice AC. Determinants of hormone therapy discontinuation among female veterans nationally. Military medicine. Jan 2008;173(1):91–96.Google Scholar
  3. 3.
    Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol. Sep 2012;120(3):595–603.Google Scholar
  4. 4.
    The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. Mar 2012;19(3):257–271.Google Scholar
  5. 5.
    Moyer VA. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. 2013;158(1):47–54.Google Scholar
  6. 6.
    Stuenkel CA, Gass ML, Manson JE, et al. A decade after the Women’s Health Initiative--the experts do agree. Menopause. Aug 2012;19(8):846–847.Google Scholar
  7. 7.
    Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA : the journal of the American Medical Association. Apr 14 2004;291(14):1701–1712.Google Scholar
  8. 8.
    LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA : the Journal of the American Medical Association. Apr 6 2011;305(13):1305–1314. Google Scholar
  9. 9.
    Jungheim ES, Colditz GA. Short-term use of unopposed estrogen: a balance of inferred risks and benefits. JAMA : the Journal of the American Medical Association. Apr 6 2011;305(13):1354–1355. Google Scholar
  10. 10.
    Ness J, Aronow WS, Newkirk E, McDanel D. Use of hormone replacement therapy by postmenopausal women after publication of the Women’s Health Initiative Trial. The journals of gerontology. Series A, Biological sciences and medical sciences. Apr 2005;60(4):460–462.Google Scholar
  11. 11.
    Ness J, Aronow WS. Prevalence and causes of persistent use of hormone replacement therapy among postmenopausal women: a follow-up study. American journal of therapeutics. Mar-Apr 2006;13(2):109–112. Google Scholar
  12. 12.
    Haimov-Kochman R, Barak-Glantz E, Ein-Mor E, et al. Duration not severity of the climacteric syndrome predicts resumption of hormone therapy after discontinuation: a prospective cohort study. Human reproduction. Sep 2006;21(9):2450–2454. Google Scholar
  13. 13.
    Newton KM, Reed SD, Nekhyludov L, et al. Factors Associated with Successful Discontinuation of Hormone Therapy. J Womens Health (Larchmt). Jan 20 2014.Google Scholar
  14. 14.
    Dumas JA, Albert KM, Naylor MR, Sites CK, Benkelfat C, Newhouse PA. The effects of age and estrogen on stress responsivity in older women. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. Sep 2012;20(9):734–743.Google Scholar
  15. 15.
    Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. The American journal of psychiatry. Dec 2004;161(12):2238–2244.Google Scholar
  16. 16.
    Toffol E, Heikinheimo O, Partonen T. Associations between psychological well-being, mental health, and hormone therapy in perimenopausal and postmenopausal women: results of two population-based studies. Menopause. Dec 30 2012.Google Scholar
  17. 17.
    Frayne SM, Phibbs CS, Berg E, et al. Sourcebook: Women Veterans in the Veterans Health Administration. Volume 2. Sociodemographics and Use of VHA and Non-VA Care (Fee). Washington, D.C.: Women’s Health Evaluation Initiative, Women’s Health Services, Veterans Health Administration, Department of Veterans Affairs;2012 (October).Google Scholar
  18. 18.
    Haskell SG, Bean-Mayberry B, Gordon K. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms? Menopause. May-Jun 2009;16(3):494–499.Google Scholar
  19. 19.
    Haskell SG. After the Women’s Health Initiative: Postmenopausal women’s experiences with discontinuing estrogen replacement therapy. J Womens Health (Larchmt). May 2004;13(4):438–442. Google Scholar
  20. 20.
    Zinzow HM, Grubaugh AL, Monnier J, Suffoletta-Maierle S, Frueh BC. Trauma among female veterans: a critical review. Trauma Violence Abuse. Oct 2007;8(4):384–400. Google Scholar
  21. 21.
    Schmidt PJ, Rubinow DR. Sex hormones and mood in the perimenopause. Annals of the New York Academy of Sciences. Oct 2009;1179:70–85.Google Scholar
  22. 22.
    Stekhoven DJ, Buhlmann P. MissForest--non-parametric missing value imputation for mixed-type data. Bioinformatics. Jan 1 2012;28(1):112–118.Google Scholar
  23. 23.
    Goodman NF, Cobin RH, Ginzburg SB, Katz IA, Woode DE. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause: executive summary of recommendations. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. Nov-Dec 2011;17(6):949–954.Google Scholar
  24. 24.
    Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA : the journal of the American Medical Association. Oct 2 2013;310(13):1353–1368.Google Scholar
  25. 25.
    de Villiers TJ, Stevenson JC. The WHI: the effect of hormone replacement therapy on fracture prevention. Climacteric. Jun 2012;15(3):263–266.Google Scholar
  26. 26.
    Lehavot K, Hoerster KD, Nelson KM, Jakupcak M, Simpson TL. Health indicators for military, veteran, and civilian women. American journal of preventive medicine. May 2012;42(5):473–480.Google Scholar
  27. 27.
    Glover EM, Jovanovic T, Mercer KB, et al. Estrogen levels are associated with extinction deficits in women with posttraumatic stress disorder. Biol Psychiatry. Jul 1 2012;72(1):19–24.Google Scholar
  28. 28.
    Glover EM, Mercer KB, Norrholm SD, et al. Inhibition of fear is differentially associated with cycling estrogen levels in women. J Psychiatry Neurosci. Apr 23 2013;38(3):120-129.Google Scholar
  29. 29.
    Lebron-Milad K, Graham BM, Milad MR. Low estradiol levels: a vulnerability factor for the development of posttraumatic stress disorder. Biol Psychiatry. Jul 1 2012;72(1):6–7.Google Scholar
  30. 30.
    Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry. Nov 1 1998;44(9):839–850. Google Scholar
  31. 31.
    Lokuge S, Frey BN, Foster JA, Soares CN, Steiner M. Depression in women: windows of vulnerability and new insights into the link between estrogen and serotonin. The Journal of clinical psychiatry. Nov 2011;72(11):e1563-1569.Google Scholar
  32. 32.
    Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S, Ferdousi T. The role of anxiety and hormonal changes in menopausal hot flashes. Menopause. May-Jun 2005;12(3):258–266.Google Scholar
  33. 33.
    Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women’s Health across the Nation. Obstet Gynecol Clin North Am. Sep 2011;38(3):489–501.Google Scholar
  34. 34.
    Thurston RC, Bromberger JT, Joffe H, et al. Beyond frequency: who is most bothered by vasomotor symptoms? Menopause. Sep-Oct 2008;15(5):841–847.Google Scholar
  35. 35.
    Hunter MS, Chilcot J. Testing a cognitive model of menopausal hot flushes and night sweats. Journal of psychosomatic research. Apr 2013;74(4):307–312.Google Scholar
  36. 36.
    Thurston RC, Bromberger J, Chang Y, et al. Childhood abuse or neglect is associated with increased vasomotor symptom reporting among midlife women. Menopause. Jan-Feb 2008;15(1):16–22.Google Scholar
  37. 37.
    Kelly UA, Skelton K, Patel M, Bradley B. More than military sexual trauma: interpersonal violence, PTSD, and mental health in women veterans. Res Nurs Health. Dec 2011;34(6):457–467.Google Scholar
  38. 38.
    Rasmusson AM, Vythilingam M, Morgan CA, 3rd. The neuroendocrinology of posttraumatic stress disorder: new directions. CNS Spectr. Sep 2003;8(9):651–656, 665–657. Google Scholar
  39. 39.
    Suris A, Lind L. Military sexual trauma: a review of prevalence and associated health consequences in veterans. Trauma Violence Abuse. Oct 2008;9(4):250–269. Google Scholar
  40. 40.
    Nicolaidis C, Curry M, McFarland B, Gerrity M. Violence, mental health, and physical symptoms in an academic internal medicine practice. J Gen Intern Med. Aug 2004;19(8):819–827.Google Scholar
  41. 41.
    Gerber MR, Wittenberg E, Ganz ML, Williams CM, McCloskey LA. Intimate partner violence exposure and change in women’s physical symptoms over time. J Gen Intern Med. Jan 2008;23(1):64–69.Google Scholar
  42. 42.
    Gardella C, Johnson KM, Dobie DJ, Bradley KA. Prevalence of hysterectomy and associated factors in women Veterans Affairs patients. The Journal of reproductive medicine. Mar 2005;50(3):166–172.Google Scholar
  43. 43.
    Lamvu G. Role of hysterectomy in the treatment of chronic pelvic pain. Obstet Gynecol. May 2011;117(5):1175–1178.Google Scholar
  44. 44.
    Latthe P, Mignini L, Gray R, Hills R, Khan K. Factors predisposing women to chronic pelvic pain: systematic review. BMJ. Apr 1 2006;332(7544):749–755.Google Scholar
  45. 45.
    Liu CF, Bryson CL, Burgess JF, Jr., Sharp N, Perkins M, Maciejewski ML. Use of outpatient care in VA and Medicare among disability-eligible and age-eligible veteran patients. BMC Health Serv Res. 2012;12:51.Google Scholar
  46. 46.
    Kroenke CH, Caan BJ, Stefanick ML, et al. Effects of a dietary intervention and weight change on vasomotor symptoms in the Women’s Health Initiative. Menopause. Sep 2012;19(9):980–988.Google Scholar
  47. 47.
    Das SR, Kinsinger LS, Yancy WS, Jr., et al. Obesity prevalence among veterans at Veterans Affairs medical facilities. American journal of preventive medicine. Apr 2005;28(3):291–294.Google Scholar

Copyright information

© Society of General Internal Medicine 2014

Authors and Affiliations

  • Megan R. Gerber
    • 1
    • 2
    Email author
  • Matthew W. King
    • 3
    • 4
  • Suzanne L. Pineles
    • 3
    • 4
  • Shannon Wiltsey-Stirman
    • 3
    • 4
  • Bevanne Bean-Mayberry
    • 5
    • 6
  • Sandra J. Japuntich
    • 3
    • 4
  • Sally G. Haskell
    • 7
    • 8
  1. 1.Women Veterans ProgramVA Boston Healthcare SystemBostonUSA
  2. 2.Department of MedicineBoston University School of MedicineBostonUSA
  3. 3.National Center for PTSD, Women’s Health Sciences DivisionVA Boston Healthcare SystemBostonUSA
  4. 4.Department of PsychiatryBoston University School of MedicineBostonUSA
  5. 5.VA Greater Los Angeles Healthcare SystemLos AngelesUSA
  6. 6.Department of MedicineUCLA David Geffen School of MedicineLos AngelesUSA
  7. 7.Department of Medicine, VA Connecticut Healthcare SystemSection of General Internal MedicineWest HavenUSA
  8. 8.Department of Medicine, Section of General Internal MedicineYale University School of MedicineNew HavenUSA

Personalised recommendations